Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| HOWL | 144 | bearish | 6/10 | A cluster of 8 Form 144 filings by MPM-affiliated entities (MPM Oncology Innovations Fund, MPM Asset Management, UBS Onc | May 28, 2026 |
| ALLO | PRESS-RELEASE | neutral | 3/10 | Allogene Therapeutics announced a planned CEO transition: Dr. David Chang will step down as President and CEO effective | May 28, 2026 |
| PTHS | 8-K | neutral | 3/10 | Pelthos Therapeutics filed an 8-K announcing that CEO Scott Plesha will present and hold one-on-one investor meetings at | May 28, 2026 |
| CPRX | PREM14A | bullish | 8/10 | Catalyst Pharmaceuticals (CPRX) filed a preliminary proxy statement (PREM14A) seeking stockholder approval for its acqui | May 28, 2026 |
| CELUW | 8-K | bearish | 6/10 | Celularity Inc. entered into a Settlement Agreement with Helena Global Investment Opportunities 1 Ltd to resolve existin | May 28, 2026 |
| RPRX | CLUSTER | neutral | 4/10 | Two senior executives at Royalty Pharma sold a combined $4.2M in open-market sales over a 7-day window, including the CF | May 28, 2026 |
| FOXOW | 8-K | neutral | 4/10 | FOXO Technologies entered into a Strategic Technology License Agreement with its founder, Jon R. Sabes, and his entity L | May 28, 2026 |
| UTHR | CLUSTER | neutral | 3/10 | The CEO made an open-market purchase of $864K alongside net open-market sales of ~$870K by the CEO, CFO, and General Cou | May 28, 2026 |
| PLYX | 8-K | neutral | 5/10 | Polaryx Therapeutics closed a $10M PIPE financing on May 28, 2026, issuing 2,502,696 shares (~5.3% dilution) at an avera | May 28, 2026 |
| EPRX | 6-K | neutral | 2/10 | Eupraxia Pharmaceuticals filed a 6-K announcing management's participation in the Jefferies Global Healthcare Conference | May 28, 2026 |
| OCUL | CLUSTER | neutral | 3/10 | Four OCUL insiders, including the Chief Scientific Officer and Chief Development Officer, conducted open-market sales of | May 28, 2026 |
| VRDN | 8-K | bullish | 6/10 | Viridian Therapeutics voluntarily prepaid and terminated its $300M credit facility with Hercules Capital, paying off all | May 28, 2026 |
| TWST | CLUSTER | bearish | 5/10 | A substantial insider selling cluster at Twist Bioscience, concentrated on May 21-26, 2026, with CEO Emily Leproust alon | May 28, 2026 |
| SLNO | 15-12G | bearish | 8/10 | Soleno Therapeutics filed Form 15-12G to terminate its SEC registration under Section 12(g) and suspend reporting obliga | May 28, 2026 |
| BCLI | 8-K | neutral | 3/10 | Brainstorm Cell Therapeutics appointed former FDA Associate Commissioner Peter Pitts to its Board of Directors, expandin | May 28, 2026 |
| RPRX | 8-K | neutral | 4/10 | Royalty Pharma entered into a new $1.8B unsecured revolving credit facility on May 22, 2026, replacing its prior credit | May 28, 2026 |
| OTLK | PRESS-RELEASE | bearish | 7/10 | Outlook Therapeutics announces a $5.0M registered direct offering of 8.54M shares at $0.5855/share to its largest stockh | May 28, 2026 |
| ETON | 144 | bearish | 5/10 | CEO Sean Brynjelsen filed a Form 144 indicating intent to sell 120,000 common shares valued at approximately $3.89 milli | May 28, 2026 |
| PRGO | 144 | neutral | 2/10 | Former director Jeffrey B. Kindler filed a Form 144 notice of intent to sell 14,357 common shares of Perrigo (PRGO), wit | May 28, 2026 |
| AZN | 25-NSE | neutral | 2/10 | The NYSE filed a Form 25-NSE to delist a guarantor of AstraZeneca's 1.200% Notes due 2026, following the notes' redempti | May 28, 2026 |
| RDY | 6-K | neutral | 2/10 | Dr. Reddy's filed its annual Secretarial Compliance Report for FY ended March 31, 2026, certifying compliance with SEBI | May 28, 2026 |
| ABT | COURT-RULING | neutral | 1/10 | The Ninth Circuit affirmed the district court's dismissal of a pro se plaintiff's employment claims against Abbott Labor | May 28, 2026 |
| IONS | 8-K | bullish | 7/10 | Ionis partner GSK reported positive Phase 3 data for bepirovirsen in chronic hepatitis B, showing a 19% functional cure | May 28, 2026 |
| TVGN | PRESS-RELEASE | neutral | 5/10 | Tevogen Bio announced it is evaluating strategic acquisitions that could generate approximately $100 million in combined | May 28, 2026 |
| USNA | CLUSTER | neutral | 3/10 | Two USNA insiders sold $120K in shares over a 7-day window. The CFO sold $101K (5,360 shares) and a director sold $20K. | May 28, 2026 |
| ALT | PRESS-RELEASE | bullish | 7/10 | Altimmune presented new 48-week data from the IMPACT Phase 2b trial of pemvidutide in MASH at the EASL Congress 2026. Th | May 28, 2026 |
| PHAR | 6-K | neutral | 3/10 | Pharming Group N.V. filed a 6-K reporting the results of its 2026 Annual General Meeting of Shareholders, where sharehol | May 28, 2026 |
| BHST | 6-K | neutral | 3/10 | BioHarvest Sciences filed its annual meeting proxy circular on Form 6-K, setting the AGM for June 25, 2026. The filing i | May 28, 2026 |
| PMN | PRESS-RELEASE | neutral | 3/10 | ProMIS Neurosciences announced participation in five June 2026 investor conferences and reiterated its timeline for the | May 28, 2026 |
| IMNM | ANALYST-UPGRADE | bullish | 3/10 | Barclays initiated coverage on Immunome Inc. (IMNM) at Overweight with a $36 price target, implying 66% upside from the | May 28, 2026 |